Emergent BioSolutions, Inc. (EBS)
6.10
+0.19
(+3.21%)
USD |
NYSE |
Aug 31, 16:00
6.11
+0.01
(+0.16%)
After-Hours: 20:00
Emergent BioSolutions Total Long Term Debt (Quarterly) : 586.70M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 586.70M |
| March 31, 2026 | 582.20M |
| December 31, 2025 | 581.30M |
| September 30, 2025 | 669.20M |
| June 30, 2025 | 674.30M |
| March 31, 2025 | 670.80M |
| December 31, 2024 | 673.40M |
| September 30, 2024 | 673.30M |
| June 30, 2024 | 873.70M |
| March 31, 2024 | 918.90M |
| December 31, 2023 | 874.00M |
| September 30, 2023 | 876.40M |
| June 30, 2023 | 916.30M |
| March 31, 2023 | 1.411B |
| December 31, 2022 | 1.421B |
| September 30, 2022 | 1.069B |
| June 30, 2022 | 846.10M |
| March 31, 2022 | 855.70M |
| December 31, 2021 | 865.20M |
| September 30, 2021 | 873.40M |
| June 30, 2021 | 879.90M |
| March 31, 2021 | 885.40M |
| December 31, 2020 | 902.60M |
| September 30, 2020 | 900.10M |
| June 30, 2020 | 808.80M |
| Date | Value |
|---|---|
| March 31, 2020 | 811.90M |
| December 31, 2019 | 833.40M |
| September 30, 2019 | 840.80M |
| June 30, 2019 | 855.10M |
| March 31, 2019 | 754.10M |
| December 31, 2018 | 794.60M |
| September 30, 2018 | 13.50M |
| June 30, 2018 | 13.48M |
| March 31, 2018 | 13.47M |
| December 31, 2017 | 13.46M |
| September 30, 2017 | 248.99M |
| June 30, 2017 | 248.69M |
| March 31, 2017 | 248.39M |
| December 31, 2016 | 248.09M |
| September 30, 2016 | 267.79M |
| June 30, 2016 | 247.39M |
| March 31, 2016 | 247.19M |
| December 31, 2015 | 246.89M |
| September 30, 2015 | 253.00M |
| June 30, 2015 | 253.00M |
| March 31, 2015 | 251.00M |
| December 31, 2014 | 251.00M |
| September 30, 2014 | 251.00M |
| June 30, 2014 | 251.00M |
| March 31, 2014 | 251.00M |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Exelixis, Inc. | 165.93M |
| Capricor Therapeutics, Inc. | 89.56M |
| ADMA Biologics, Inc. | 202.66M |
| Akebia Therapeutics, Inc. | 209.81M |
| Arcutis Biotherapeutics, Inc. | 114.14M |